Center for Integrative Chemical Biology and Drug Discovery
Combining accomplished pharmaceutical scientists and cutting edge academicians focused on oncology drug discovery and the chemical and structural biology of chromatin regulation.
“The Center for Integrative Chemical Biology and Drug Discovery (CICBDD) combines accomplished pharmaceutical scientists and cutting edge academicians focused on oncology drug discovery and the chemical and structural biology of chromatin regulation. The first clinical candidate from the Center will enter Phase 1 trials in early 2017 and is focused on activating the innate immune system in solid tumors and leukemia. The Center’s chromatin science is centered on methyl-lysine as a posttranslational modification and the protein-protein interactions that it facilitates. The first chemical probes for methyl-lysine reader proteins were discovered in the CICBDD and will be used to validate novel interventions in cancer and other diseases.”
The center provides leadership of the North Carolina Comprehensive Chemical Biology Center, a member of NCI’s Chemical Biology Consortium.
What’s New at CICBDD?
- NCI Renews Partnership with UNC to Seek New Cancer Drugs
- New Research Funding
- Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing
- Investigational New Drug (IND) is Open for Clinical Trials on Solid Tumors
- Using New Screening Tool, UNC Researchers Identify Potential Treatments for Ewing Sarcoma
- UNC3866, A Cellular Chemical Probe Targeting the Chromodomains of Polycomb Repressive Complex 1
View Video Here: The Promise of Academic Drug Discovery